PLM-102 for Relapsed and Refractory Acute Myeloid Leukemia
This study is testing a new drug called PLM-102, given by mouth, for adults with acute myeloid leukemia (AML) that has come back (relapsed) or is not responding to treatment (refractory). The main goal is to find the highest safe dose of PLM-102 and to understand its side effects. Researchers will also look at how well PLM-102 helps patients, including how many achieve a complete response and how long that response lasts. You may be able to join if you are an adult with relapsed or refractory AML or MDS/AML (a related blood disorder). This study plans to enroll 12 participants.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 12 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Safety and side effects will be measured through study completion, which is an average of 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Abhishek Maiti, MBBS · PRINCIPAL_INVESTIGATOR · UT MD Anderson
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Safety and Adverse Events (AEs)Through study completion; an average of 1 year
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0